EPS and akathisia were similar to placebo in adults with bipolar I and bipolar II depression1,2
Incidence of EPS* and akathisia in clinical trials at 6 weeks1,2
*EPS (extrapyramidal symptoms) include akathisia, extrapyramidal disorder, muscle spasms, restlessness, dyskinesia, tremor, movement disorder, and gait disturbance.1
†Barnes Akathisia Rating Scale (BARS) ranges from 0 to 14.
‡The Abnormal Involuntary Movement Scale (AIMS) for dyskinesia (total score ranges from 0 to 28).
§The Simpson-Angus Scale (SAS) for EPS (total score ranges from 0 to 40).
Antipsychotic drugs have been reported to cause:
- Tardive Dyskinesia (TD), a syndrome of potentially irreversible, dyskinetic, and involuntary movements which may increase as the duration of treatment and total cumulative dose increases. The syndrome can develop after a relatively brief treatment period, even at low doses, or after treatment discontinuation. Given these considerations, CAPLYTA should be prescribed in a manner most likely to reduce the risk of TD. Discontinue CAPLYTA if clinically appropriate.
Helpful tools & resources
References: 1. CAPLYTA prescribing information, 2022. 2. Data on File. 2021.